BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27877018)

  • 21. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients.
    Shimamoto Y
    Cancer Detect Prev; 1995; 19(5):426-35. PubMed ID: 7585729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
    Li J; Wu XB; Zhou Y; Wang X; Chen JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CD200 protein, bad prognostic in patients with multiple myeloma].
    Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Pérez-Retiguin F; Reyes-Maldonado E; Maillet D; Montiel-Cervantes LA
    Rev Med Inst Mex Seguro Soc; 2015; 53(4):438-43. PubMed ID: 26177431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
    Bao L; Lai Y; Liu Y; Qin Y; Zhao X; Lu X; Jiang Q; Lu J; Huang X
    Leuk Res; 2013 Sep; 37(9):1083-8. PubMed ID: 23849988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
    Qian J; Jin J; Luo H; Jin C; Wang L; Qian W; Meng H
    Hematology; 2017 Sep; 22(8):472-476. PubMed ID: 28463078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.
    Wu S; Zheng C; Chen S; Cai X; Shi Y; Lin B; Chen Y
    Biomed Res Int; 2015; 2015():927105. PubMed ID: 26425561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
    Jurczyszyn A; Nahi H; Avivi I; Gozzetti A; Niesvizky R; Yadlapati S; Jayabalan DS; Robak P; Pika T; Andersen KT; Rasche L; Mądry K; Woszczyk D; Raźny M; Usnarska-Zubkiewicz L; Knopińska-Posłuszny W; Wojciechowska M; Guzicka-Kazimierczak R; Joks M; Grosicki S; Ciepłuch H; Rymko M; Vesole DH; Castillo JJ
    Br J Haematol; 2016 Dec; 175(5):884-891. PubMed ID: 27682187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
    Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
    Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment.
    Liu A; Yang G; Geng C; Wang H; Li L; Li Y; Wu Y; Tian Y; Leng Y; Wang G; Gao W; Chen W
    Acta Haematol; 2016; 135(3):140-5. PubMed ID: 26587903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors in IgD myeloma: a study of 21 cases.
    Fibbe WE; Jansen J
    Scand J Haematol; 1984 Nov; 33(5):471-5. PubMed ID: 6515330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
    Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].
    Zhu W; Lu J; Lu J; Hou J; Huang X; Chen W
    Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):741-4. PubMed ID: 26080844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments.
    Hall CJ; Doss S; Hay N; Sutcliffe F; Stevens A
    Lancet Oncol; 2016 Mar; 17(3):279-80. PubMed ID: 26827243
    [No Abstract]   [Full Text] [Related]  

  • 39. A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
    He J; Yang L; Meng X; Wei G; Wu W; Han X; Zheng G; Zheng W; Ye X; Shi J; Xie W; Zhang J; Huang H; Lin M; Cai Z
    Am J Med Sci; 2013 Feb; 345(2):88-93. PubMed ID: 22986611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
    Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
    Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.